Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: GlobeNewswire
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to transform the lives of individuals and families impacted by rare and ultrarare diseases, empower its employees, and make a meaningful impact on the communities it partners with. “In rare disease, corporate responsibility means pushing for progress and change to support drug development and access for the people and families waiting for proper care,” said Emil Kakkis, M.D., Ph.D., president and chief executive officer of Ultragenyx. “Our 2023 Corporate Responsibility Report highlights the commitment and drive of our team to do the right thing for people living with rare disease while advancing our efforts to contribute meaningfully to the communities where we work and live.” The company’s Corporate Responsibility program is structured around six key pillars – Innovation, Patients, People, C
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality [Yahoo! Finance]Yahoo! Finance
- Ultragenyx to Participate at Bank of America’s 2024 Healthcare ConferenceGlobeNewswire
- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $111.00 to $109.00. They now have a "buy" rating on the stock.MarketBeat
RARE
Earnings
- 5/2/24 - Miss
RARE
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 10-Q
- 5/2/24 - Form 8-K
- RARE's page on the SEC website